Search Results 51-60 of 17177 for GnRH

1. A Study to Evaluate the Feasibility of Daily, Long-Term, Intermittent Fasting for Men on PSA Surveillance Following Radical Prostatectomy - Mayo Clinic

   On hormone therapy (Casodex, GnRH agonist/antagonist). Participating Mayo Clinic locations. Study statuses change often. Please contact the study team for ...

2. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 as a Single Agent and In Combination With Enzalutamide in Participants With Metastatic Castrate-Resistant Prostate Cancer - Mayo Clinic

   Castration resistant disease defined as ongoing androgen deprivation therapy with gonadotropin-releasing hormone (GnRH) analogue or bilateral orchiectomy ...

3. Impact of Endogenous E2 on SSI and GH Rebound - Mayo Clinic

   About this study. Endogenous estrogens maintain growth hormone (GH) secretion in postmenopausal women by potentiating endogenous GH-releasing hormone (GHRH) ...

4. A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer - Mayo Clinic

   Currently using a GnRH agonist or antagonist (unless surgically castrated). Exclusion Criteria: Cancer-related pain requiring scheduled opioid narcotics for ...

5. MC250902 Administration Of Cancer-Directed Therapy In The Patient’s Homes Versus In Clinic In The Florida Panhandle And Surrounding Areas

   Co-administration with hormonal agents such as anti-androgens, PARP inhibitors, oral GnRh antagonists, estrogens, SERMs, or aromatase inhibitors are allowed ...

6. Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25 - Mayo Clinic

   Prior AI or GnRH for fertility preservation is allowed. - Hormonally based contraceptive measures must be discontinued prior to pre-entry (including ...

7. SNRIs ease depression by affecting chemical messengers called neurotransmitters that affect mood. SNRIs block the reabsorption, also called reuptake, ...

8. A Study of Treatment with Docetaxel and Prednisone, with or without Vaccine Therapy, for Patients who have Metastatic Hormone-Resistant Prostate Cancer - Mayo Clinic

   Received standard of care androgen deprivation treatment before trial entry (surgical castration versus gonadotropin-releasing hormone [GnRH] analogue or ...

9. Low-Dose Tamoxifen Citrate in Reducing Breast Cancer Risk in Radiation-Induced Cancer Survivors - Mayo Clinic

   ... GnRH analogs; androgens or antiandrogens; Concurrent use of warfarin and strong inhibitors or CYP2D6 will not be allowed; A personal history or a strong ...

10. A Study to Compare Elacestrant vs. Standard of Care for the Treatment of Patients with ER+/HER2- Advanced Breast Cancer - Mayo Clinic

    Fulvestrant treatment < 28 days before first dose of study drug. · Any endocrine therapy < 14 days before first dose of study drug (with the exception of GnRH ...